Pipeline dossier

NIH & clinical-trial pipeline signals for GENMAB A/S (GMAB)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for GMAB, mapped to public ticker GMAB (CIK 0001434265). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingGMAB35% conf

GENMAB A/S (GMAB) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingGMAB35% conf

GENMAB A/S (GMAB) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

JSON API for this entity →